Reading PLRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PLRX free→Reading PLRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PLRX free→QuarterlyIQ Insights · PLRX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition . On May 11, 2026, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K including the exhibits furnished herewith shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the "E…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) Departure of Directors On April 14, 2026, David E.I. Pyott, a Class I director on the Board of Directors (the “Board”) of Pliant Therapeutics, Inc. (the “Company”) and a member of the Audit Committee and the Nominating and Corporate Governance Committee of the Board, notified the Chief Executive Officer of the Company, Chairman of the Board, and…
Results of Operations and Financial Condition . On March 11, 2026, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the fourth quarter ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K including the exhibits furnished herewith shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended,…
Material Modification to Rights of Security Holders. On March 3, 2026, Pliant Therapeutics, Inc. (the “Company”) and Computershare Trust Company, N.A., as rights agent (the “Rights Agent”), entered into an Amendment to Stockholder Rights Agreement (the “Amendment”), amending the Stockholder Rights Agreement, dated as of March 12, 2025, between the Company and the Rights Agent (the “Rights Agreement”). The Amendment changes the final expiration time of the Rights (as defined in the Rights Agre…
Entry into a Material Definitive Agreement. The information set forth in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 10, 2025, Pliant Therapeutics, Inc.’s (the “Company”) Board of Directors (the “Board”) appointed Minnie Kuo as Chief Operating Officer, effective immediately. Ms. Kuo, age 45, joined the Company in September 2023 as Chief Development Officer and served in such position until her appointment as Chief Operating Officer. She is an experien…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 2, 2025, Pliant Therapeutics, Inc. (the “Company”) notified Éric Lefebvre, M.D., Chief Medical Officer, that Dr. Lefebvre’s employment with the Company will terminate effective December 15, 2025 (the “Separation Date”). The Company expects that Dr. Lefebvre will continue to assist the Company as a consultant after the Separation Date in…
Results of Operations and Financial Condition . On November 6, 2025, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K including the exhibits furnished herewith shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 20, 2025, Pliant Therapeutics, Inc. (the “Company”) received and accepted the resignation of Hans Hull as Chief Business Officer of the Company, effective that same day. Mr. Hull’s resignation was not due to a disagreement on any matter related to the Company’s operations, policies or practices. SIGNATURES Pursuant to the requirements of…
Termination of a Material Definitive Agreement On October 14, 2025, Pliant Therapeutics, Inc. (the “Company”) completed a voluntary prepayment of $32.4 million, representing all outstanding principal, accrued and unpaid interest, fees, costs and expenses (the “Payoff Amount”) under the Amended and Restated Loan and Security Agreement (the “Loan Agreement”) dated as of March 11, 2024 among the Company, Oxford Finance LLC, as collateral agent, and the lenders listed on Schedule 1.1 thereof or o…
Results of Operations and Financial Condition . On August 7, 2025, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the second quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K including the exhibits furnished herewith shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the…
Results of Operations and Financial Condition . On May 8, 2025, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K including the exhibits furnished herewith shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the "Ex…
Costs Associated with Exit or Disposal Activities. On May 1, 2025, Pliant Therapeutics, Inc. (the “Company”) announced a reduction in its workforce that will impact approximately 45% of its current employees. The Company expects to substantially complete the workforce reduction by the end of the second quarter of 2025. The Company expects to recognize approximately $3.6 million in total for severance and related benefits for employees laid off under the reduction in force. These charges are p…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 1, 2025, the Company announced that in connection with the workforce reduction, the employment of Mike Ouimette, the Company’s Chief Legal and Compliance Officer and Corporate Secretary, would terminate effective May 1, 2025. Forward-Looking Statements This current report on Form 8-K contains forward-looking statements about the business pro…
Results of Operations and Financial Condition . On March 3, 2025, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the fourth quarter ended December 31, 2024. A copy of this press release is furnished as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K including the exhibits furnished herewith shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, t…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.